SUMMARY The activation of phospholipase A2 is believed to have an important role in the inflammatory process owing to its induction of eicosanoids, platelet activating factor, and other mediators. Soluble phospholipase A2 has been associated with exudates in different inflammatory conditions. In this review the general physiology and control of this enzyme and, in particular, the most recent findings on human synovial fluid phospholipase A2s are discussed.
Phospholipase B hydrolyses both acyl groups, phospholipase C cleaves the glycerol phosphate bond, and phospholipase D removes the base group.' Phospholipase A2 was the first of the phospholipases to be recognised over a century ago when Bokay found that phosphatidylcholine was degraded by a component of pancreatic juice2; which is now known to be the pancreatic phospholipase A2. In mammalian cells phospholipase A2 can be found as membrane associated and extracellular (soluble), thought to be released from lysosomal stores upon The anti-inflammatory efficacy of certain steroidal and non-steroidal drugs may partially reside in their ability to inactivate extracellular phospholipase A2. The anti-inflammatory effect of corticosteroids has been explained by the induction of lipocortin synthesis, and lipocortin has been claimed to be a specific, non-competitive inhibitor of phospholipase A2.27 28 It has recently been reported that some patients with systemic lupus erythematosus and rheumatoid arthritis have antibodies against lipocortin.27 29 The possibility that inhibition of lipocortin leads to an increase of phospholipase A2 activity in arthritic patients should thus be considered. There is no conclusive evidence that aspirin and related non-steroidal anti-inflammatory drugs have effects on phospholipase A2, though indomethacin has been reported to inhibit phospholipase A2 through inhibition of calcium transport.30
On the other hand, hydroxychloroquine and mepacrine, two 
